Outside advisers to the U.S. Food and Drug Administration recommended broader access to six unapproved peptides, capping a two-day review that backed most of the compounds despite the health regulator’s staff concerns about limited safety and effectiveness data. Over the course of the meeting held on Thursday and Friday, the panel voted to recommend the FDA allow compounding pharmacies to manufacture six out of seven peptides being considered for patients with a prescription, reversing Biden-era restrictions criticized by Health Secretary Robert F. Kennedy Jr.
Read the full article: FDA Advisers Recommend Relaxing US Rules on Compounding Peptides //
Source: https://www.reuters.com/legal/litigation/fda-advisers-weigh-relaxing-rules-three-more-peptides-widen-access-2026-07-24/